Method and system for treating depressive and anxiety disorders

Details Method and system for treating depressive and anxiety disorders Method and system for treating depressive and anxiety disorders

2006-05-30

2006-05-30

Sirmons, Kevin C. (Department: 3767)

Surgery

Means for introducing or removing material from body for...

Treating material introduced into or removed from body...

C604S508000

Reexamination Certificate

active

07052486

ABSTRACT:
A method and system for treating depressive and anxiety disorders is disclosed. The method and system of the present invention comprises operating a programmable pump for the delivery of at least one therapeutic substance into the cerebrospinal fluid of a patient for the treatment of depressive or anxiety disorders. In an embodiment, a sensor implanted in a patient may be used in combination with the programmable pump and catheter.

REFERENCES:
patent: 3882245 (1975-05-01), Du Charme
patent: 5599560 (1997-02-01), Siuciak
patent: 6176242 (2001-01-01), Rise
Sussman, N., (1994), “The Potential Benefits of Serotonin Receptor-Specific Agents,”J Clin Psychiatry55: 45-51.
Thase, M.E., Frazer, A., Gorman, J.M., Hirschfeld, R.M. and Roose, S.P., (2000), “Pharmacotherapy of Depression: New Strategies,”A Symposium of the American Psychiatric Association 2000 Annual Meeting.
Howe, J. and Yaksh, T.L. (1982), “Changes in Sensitivity to Intrathecal Norepinephrine and Serotonin after 6-Hydroxydopamine, 5, 6-Dihydroxytryptamine or Repeated Monoamine Administration,”J Pharmacol Exp Ther220: 311-321.
Borszcz, George S., Johnson, Christine P., and Williams, Daniel H.“Increases in Vocalization and Motor Reflex Theresholds Generated by the Intrathecal Administration of Serotonin or Norepinephrine,”Behavioral Neuroscience, (1996) vol. 110, No. 4, 809-822.
Milne, B2, Cervenko, F., Jhamandas, K., Loomis C. and Sutak, M., (1985), “Analgesia and Tolerance to Intrathecal Morphine and Norepinephrine Infusion via Implanted Mini-osmotic Pumps in the Rat,”Pain22: 165-172.
Minor, B.G.1, Persson, M.1, Post, C.1, Jonsson G.1(1988), “Intrathecal Noradrenaline Restores 5-Methoxy-N, N-dimethyltryptamine Induced Antinociception Abolished by Intrathecal 6-Hydroxydopamine,”J Neural Trasm72: 107-120.
Brustein, E. and Rossignol, S. (1999), “Recovery of Locomotion After Ventral and Ventrolateral Spinal Lesions in the Cat. II. Effects of Noradrenergic and Serotoninergic Drugs,”American Physiological Society1513-1530.
Weisenfeld-Hallin, Z., (1987), “Intrathecal Noradrenaline has a Dose-Dependent Inhibitory or Facilitatory Effect on the Flexion Reflex in the Rat,”Acta Physiol Scand130: 507-511.
Leonard, B.E., (1997). “Noradrenaline in Basic Models of Depression,”Eur Neuropsychophamacol7: S11-S16.
Kramer, M.S., et al.(1998), “Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors,”Sciencevol. 281 Sep. 11, 1640-1625.
Keller, M.B., Schatzberg, A.F., Charney, D.S. Krishnan, K.R.,Weissman, M.M. and Nemeroff, C.B. (2000), “Novel Treatments of Depression,”A symposium held at the 2000 Annual Meeting of the APA.
Arborelius, L., M J Owens, P M Plotsky and C B Nemeroff, “The role of corticotropin-releasing factor in depression and anxiety disorders”,Journal of Endocrinology(1999) 160; 1-12.
Carl Salzman, M.D. “Substance P in Depression”,Harvard Health Publications; Dec. 2001.
Bender, Kenneth J., Pharm. D., M.A., “Substance P'Antagonist Relieves Depression,”Psychiatric Times, (Nov. 1998) vol. XV, issue 11.
Theodore L. Munsat, M.D., James Taft, PA-C and Ivor M.D. Jackson, M.D., “Pharmacokinetics of intrathecal thyrotropin-releasing hormone”,Neurology(1987) 37:597-601.
Albert Sattin, “A Heuristic Model of Mental Depression Derived from Basic and Applied Research on Thyrotropin-Releasing Hormone,”THYROID, vol. 8, No. 10 (1998).
Potter, William Z, and Manji, Husseini K., “Catecholamines in Depression: An Update,”Clinical Chemistryvol. 40, No. 2 (1994).
Brian E. Leonard, “The role of noradrenaline in depression: a review”,Journal of Psychopharmacology, vol. II No. 4 (1997) 539-547.
Cleare, A.J., Murray, M., Sherwood, R.A. and O'Keane V., “Abnormal 5-HT1Dreceptor function in major depression: a neuropharmacological challenge study using sumatriptan,”Psychological Medicine(1998) 28: 295-300.
Spina M.G., et al, “Behavioral effects of central administration of the novel CRF antagonist astressin in rats,”Neuropsychopharmacology, Mar 22, 2000 (3) 230-9.
“Depression,”National Institute of Mental Health, Publication No. 00-3561 (2000).
Janicak, P.G. and Martis, B. (1998), “Strategies for Treatment-Resistant Depression”,Clinical Cornerstore1:58-71.
Shelton, R.C. (1999), “Treatment Options for Refractory Depression,”J Clin. Psychiatry60:57-63.
Joffe, R.T. (1997), “Refractory Depression: Treatment Strategies, with Particular Reference to the Thyroid Axis,”J. Psychiatry Neurosci.22:327-331.
“Anxiety Disorders,”National Institute of Mental Health, Publication No. 00-3879(2000) .
Walter, G., Rey, J.M., and Mitchel, P.B. (1999), “Practitioner Review: Electroconvulsive Therapy in Adolescents,”J. Child Psychiatry40: 325-334.
Sackeim, H. A., Prudic, J., et al. (1990) “The Impact of Medication Resistance and Continuation Pharmacotherapy on Relapse Following Response To Electroconvulsive Therapy in Major Depression,”J Clin Psychopharmacol10:96-104.
ITIL, T.M., Patterson, C.D., Polvan, N., Bigelow, A. and Bergey, B. (1975), “Clinical and CNS Effects of Oral and I.V. Thyrotropin-Releasing Hormone in Depressed Patients,”Dis Nerv Sys2: 529-536.
Prange, A.J., Wilson, I.C., Lara, P.P., Alltop, L.B. and Breese, G.R. (1972), “Effects of Thyrotropin-Releasing Hormone in Depression,”Lancet2:999-1002.
Callahan, A.M., Frye, M.A., Marangell, L.B., George, M.S. Ketter, T.A., L'Herrou, T.A. and Post R.M., (1997), “Comparative Antidepressant Effects of Intravenous and Intrathecal Thyrotropin-Releasing Hormone: Confounding Effects of Tolerance and Implications for Therapeutics,”Biol. Psychiatry41: 264-272.
Marangell, L.B., George, M. S., Callahan, A.M., Ketter, T.A., Pazzaglia, P.J., L'Herrou, T.A., Leverich, G.S. and Post, R.M., (1997), “Effects of Intrathecal Thyrotropin-Releasing Hormone (Protirelin) in Refractory Depressed Patients,”Arch. Gen. Psychiatry 54:214-222.
Stern L., Zohar, J., Cohen, R., and Sasson, Y., (1998), “Treatment of Severe, Drug Resistant Obsessive Compulsive Disorder with 5HT1Dagonist Sumatriptan,”Eur Neuropsychopharmacol8: 325-328.
Saxena, P.R. (1991), “Migraine Therapy and 5-HT Receptor Activity,”J Neurol238: S36-S37.
Arranz, B., Eriksson, A., Mellerup, E., Plenge, P. and Marcusson, J., (1994), “Brain 5HT1A,5HT1D,and 5HT2Receptors in Suicide Victims,”Biol Psychiatry35: 457-463.
Deakin, J.F.W., (1988), “5HT2Receptors, Depression and Anxiety,”Pharmacol Biochem Behav29: 819-830.
Feighner, J.P., (1999), “Mechanism of Action of Antidepressant Medications,”J Clin Psychiatry60: 4-13.
Ruoff, G.E., (1996), “Depression in the Patient with Chronic Pain,”J Fam Pract43: S25-S34.

Affiliated with

Also associated with

Rating

Method and system for treating depressive and anxiety disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method and system for treating depressive and anxiety disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and system for treating depressive and anxiety disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3598680